SOBI (SOBI) investor relations material

Financial performance and growth

• Achieved 26% growth at constant exchange rates (CER) in H1 2026, with a 37% adjusted EBITA margin.

• Q2 2026 net sales grew 29% at CER, with strong contributions from all regions and key products.

• Doptelet sales rose 36% in Q2, establishing it as a leading global franchise with expanding international launches.

• Altuvoct sales increased 149% YoY in Q2, with launches in 30 countries and further expansion planned.

• Full-year 2026 revenue is now expected to grow by a mid- to high-teens percentage at CER, with adjusted EBITA margin in the mid- to high-30s.

Pipeline and product development

• Strong pipeline momentum with multiple launches and regulatory filings, including Aspaveli in nephrology and Tryngolza for sHTG.

• Pozdeutinurad showed meaningful urate reduction in REDUCE 2; NASP received a CRL with a clear resubmission path.

• Gamifant EMBRACE II pivotal study for IDS to initiate in H2 2026, following EMA feedback.

• Sobi-Innate Pharma partnership for Lacutamab in CTCL, with Phase 3 trials and potential accelerated approval for Sezary Syndrome.

• Six major ongoing or upcoming launches are expected to drive future growth.

Strategic outlook and long-term ambition

• Updated 2026 outlook reflects strong H1 performance and pipeline progress, with resource reallocation and cost control.

• Investments in launches and clinical programs, including Gamifant IDS and NASP, are prioritized for future revenue growth.

• Ambition to double revenue to 55bn SEK by 2030, driven by portfolio renewal and major product launches.

• Strategic growth supported by foundational and new products, with a focus on international expansion.

• Loss of exclusivity and portfolio renewal are key considerations in the long-term plan.